BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee CM, Ong GY, Lu SN, Wang JH, Liao CA, Tung HD, Chen TM, Changchien CS. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation. J Hepatol. 2002;37:669-674. [PMID: 12399235 DOI: 10.1016/s0168-8278(02)00267-2] [Cited by in Crossref: 55] [Cited by in F6Publishing: 15] [Article Influence: 3.1] [Reference Citation Analysis]
Number Citing Articles
1 Alexander G, Baba CS, Chetri K, Negi TS, Choudhuri G. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial. BMC Gastroenterol 2005;5:29. [PMID: 16164746 DOI: 10.1186/1471-230X-5-29] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
2 Fong TL, Tien A, Jo KJ, Chu D, Cheung E, Mena EA, Phan QQ, Yu AS, Mohammed W, Velasco A. Durability of Hepatitis B e Antigen Seroconversion in Chronic Hepatitis B Patients Treated with Entecavir or Tenofovir. Dig Dis Sci. 2015;60:3465-3472. [PMID: 26138653 DOI: 10.1007/s10620-015-3775-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
3 Yao CC, Hung CH, Hu TH, Lu SN, Wang JH, Lee CM, Chen CH. Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL. Sci Rep 2017;7:1839. [PMID: 28500322 DOI: 10.1038/s41598-017-02010-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 5.0] [Reference Citation Analysis]
4 Yu W, Zhao C, Shen C, Wang Y, Lu H, Fan J. The efficacy and safety of Nucleos(t)ide analogues in patients with spontaneous acute exacerbation of chronic hepatitis B: a systematic review and meta-analysis. PLoS One 2013;8:e65952. [PMID: 23776577 DOI: 10.1371/journal.pone.0065952] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
5 Sonneveld MJ, Janssen HL. Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B. Curr Hepat Rep. 2010;9:91-98. [PMID: 20461129 DOI: 10.1007/s11901-010-0041-7] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.9] [Reference Citation Analysis]
6 Song MJ, Song DS, Kim HY, Yoo SH, Bae SH, Choi JY, Yoon SK, Paik YH, Lee JS, Lee HW, Kim HJ. Durability of viral response after off-treatment in HBeAg positive chronic hepatitis B. World J Gastroenterol 2012; 18(43): 6277-6283 [PMID: 23180949 DOI: 10.3748/wjg.v18.i43.6277] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 28] [Article Influence: 3.0] [Reference Citation Analysis]
7 Liu CJ, Huang WL, Chen PJ, Lai MY, Kao JH, Chen DS. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B. World J Gastroenterol 2004; 10(24): 3574-3578 [PMID: 15534909 DOI: 10.3748/wjg.v10.i24.3574] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.5] [Reference Citation Analysis]
8 Xi D, Luo X, Ning Q. Detection of HBV and HCV coinfection by TEM with Au nanoparticle gene probes. J Huazhong Univ Sci Technolog Med Sci 2007;27:532-4. [PMID: 18060628 DOI: 10.1007/s11596-007-0514-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
9 Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, Hung CH. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol 2014; 20(24): 7686-7695 [PMID: 24976706 DOI: 10.3748/wjg.v20.i24.7686] [Cited by in CrossRef: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
10 Xie L, Liao G, Chen H, Xia M, Huang X, Fan R, Peng J, Zhang X, Liu H. Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B. BMC Infect Dis 2019;19:640. [PMID: 31324231 DOI: 10.1186/s12879-019-4261-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
11 Lee HA, Seo YS, Park SW, Park SJ, Kim TH, Suh SJ, Jung YK, Kim JH, An H, Yim HJ, Yeon JE, Byun KS, Um SH. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B. Clin Mol Hepatol. 2016;22:382-389. [PMID: 27729633 DOI: 10.3350/cmh.2016.0047] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
12 Yue-Meng W, Yang LH, Yang JH, Xu Y, Yang J, Song GB. The effect of plasma exchange on entecavir-treated chronic hepatitis B patients with hepatic de-compensation and acute-on-chronic liver failure. Hepatol Int. 2016;10:462-469. [PMID: 26482576 DOI: 10.1007/s12072-015-9667-4] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 5.7] [Reference Citation Analysis]
13 Lee HC, Suh DJ, Ryu SH, Kim H, Shin JW, Lim YS, Chung YH, Lee YS. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion. Gut. 2003;52:1779-1783. [PMID: 14633962 DOI: 10.1136/gut.52.12.1779] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.1] [Reference Citation Analysis]
14 Tawada A, Kanda T, Yokosuka O. Current and future directions for treating hepatitis B virus infection. World J Hepatol 2015; 7(11): 1541-1552 [PMID: 26085913 DOI: 10.4254/wjh.v7.i11.1541] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 3.3] [Reference Citation Analysis]
15 Pan X, Zhang K, Yang X, Liang J, Sun H, Li X, Zou Y, Xu Q, An G, Li G. Relapse rate and associated-factor of recurrence after stopping NUCs therapy with different prolonged consolidation therapy in HBeAg positive CHB patients. PLoS One. 2013;8:e68568. [PMID: 23844222 DOI: 10.1371/journal.pone.0068568] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]